Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | PHGDH | O43175 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9996956 | 0.85 | KMT2A (0.60) | EPHX2LRRK2PKMGLAKMT2A | |
| SCHEMBL4246868 | 0.85 | EPHX2 (0.54) | EPHX2KMT2AHPGDL3MBTL1KCNH2 | |
| SCHEMBL20750406 | 0.85 | PKM (0.50) | PKMHPGDKCNH2 | |
| SCHEMBL17076704 | 0.84 | KMT2A (0.50) | EPHX2LRRK2PKMGLAKMT2A | |
| SCHEMBL12698702 | 0.84 | HSD11B1 (0.45) | EPHX2KMT2AL3MBTL1 | |
| SCHEMBL29492972 | 0.83 | KMT2A (0.67) | LRRK2PKMGLAKMT2AHSP90AA1 | |
| SCHEMBL1912012 | 0.83 | KMT2A (0.67) | LRRK2PKMGLAKMT2AHSP90AA1 | |
| SCHEMBL17076877 | 0.82 | LRRK2 (0.51) | LRRK2PKMGLAKMT2AMLYCD | |
| SCHEMBL4163446 | 0.80 | HSP90AA1 (0.58) | EPHX2PKMKMT2AMLYCDHSP90AA1 | |
| SCHEMBL7459022 | 0.80 | LRRK2 (0.52) | LRRK2PKMGLAKMT2AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | EPHX2 4581/4885LRRK2 1/4885PKM 761/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | EPHX2 4367/4885LRRK2 1/4885PKM 478/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | EPHX2 4581/4885LRRK2 1/4885PKM 761/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | EPHX2 4636/4885LRRK2 1/4885PKM 766/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | EPHX2 4636/4885LRRK2 1/4885PKM 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.